How to buy Century Therapeutics stock (Century Therapeutics)

Century Therapeutics is a biotechnology business based in the US. Century Therapeutics shares (IPSC) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.10 – a decrease of 9.84% over the previous week. Century Therapeutics employs 152 staff and has a trailing 12-month revenue of around $2.7 million.

Our top picks for where to buy Century Therapeutics stock

Buy Century Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Century Therapeutics stock price (NASDAQ: IPSC)

Use our graph to track the performance of IPSC stocks over time.

Century Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$1.10
52-week range	$0.98 - $5.51
50-day moving average more info button	$1.40
200-day moving average more info button	$2.43
Wall St. target price	$9.67
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.83

Is it a good time to buy Century Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Century Therapeutics price performance over time

Historical closes compared with the close of $1.1 from 2024-12-20

1 week (2024-12-16)	-5.98%
1 month (2024-11-22)	-9.09%
3 months (2024-09-23)	-29.03%
6 months (2024-06-21)	-61.54%

1 year (2023-12-22)	-54.55%
2 years (2022-12-23)	-80.60%
3 years (2021-12-23)	18.17
5 years (2019-12-19)	N/A

Century Therapeutics financials

Revenue TTM	$2.7 million
Gross profit TTM	$5.2 million
Return on assets TTM	-20.9%
Return on equity TTM	-62.61%
Profit margin	0%
Book value	$2.31
Market Capitalization more info button	$88.9 million

TTM: trailing 12 months

Century Therapeutics share dividends

We're not expecting Century Therapeutics to pay a dividend over the next 12 months.

You may also wish to consider:

• Pfizer (PFE.US) (6.64% forward annual dividend yield)

Century Therapeutics share price volatility

Over the last 12 months, Century Therapeutics's shares have ranged in value from as little as $0.98 up to $5.51. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Century Therapeutics's is 1.42. This would suggest that Century Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

To put Century Therapeutics's beta into context you can compare it against those of similar companies.

• Prelude Therapeutics Inc (PRLD.US): 1.546
• Greenwich Lifesciences Inc (GLSI.US): 3.318
• Pfizer (PFE.US): 0.615

Century Therapeutics overview

Century Therapeutics, Inc. , a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania. .

Frequently asked questions

null
What percentage of Century Therapeutics is owned by insiders or institutions?
Currently 28.069% of Century Therapeutics shares are held by insiders and 61.114% by institutions. How many people work for Century Therapeutics?
Latest data suggests 152 work at Century Therapeutics. When does the fiscal year end for Century Therapeutics?
Century Therapeutics's fiscal year ends in December. Where is Century Therapeutics based?
Century Therapeutics's address is: 25 North 38th Street, Philadelphia, PA, United States, 19104 What is Century Therapeutics's ISIN number?
Century Therapeutics's international securities identification number is: US15673T1007